ArticleWorld journal of surgical oncology2025
SCNN1A expression in triple-negative breast cancer: clinical implications for prognosis and neoadjuvant therapy response.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThis study aimed to identify differential genes between pathological complete response (pCR) and non-pCR following neoadjuvant chemotherapy in triple-negative breast cancer (TNBC). Additionally, the expression and clinical significance of the differential gene SCNN1A in TNBC were explored.
methodsDifferential genes related to prognosis following neoadjuvant chemotherapy in TNBC were identified using the GEO database. Core genes were selected through the Cytoscape visualization and support vector machine (SVM) feature selection. The prognostic significance of these genes was assessed via online databases. SCNN1A expression and its correlation with clinicopathological data and neoadjuvant chemotherapy response were analyzed in 283 TNBC patients from the First Affiliated Hospital of Bengbu Medical University using immunohistochemistry.
resultsEleven core genes, including SCNN1A, were identified from 912 differential genes. High SCNN1A expression was associated with poor prognosis in TNBC patients via online database analysis. Gene set difference analysis (GSVA) and Gene set enrichment analysis (GSEA) revealed that SCNN1A was involved in several metabolic pathways. The clinical data indicated that high SCNN1A expression was associated with advanced T (p = 0.037) and N stages (p = 0.011), but not with age, HER2 status, Ki-67 expression, or histological grade. High SCNN1A expression was significantly more frequent in non-pCR patients compared to pCR patients, and high SCNN1A expression was associated with significantly lower overall survival (OS) and disease-free survival (DFS).
conclusionSCNN1A overexpression is associated with poor prognosis and non-pCR status in TNBC patients undergoing neoadjuvant chemotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.